Skip to Main Content

Naftali Kaminski, MD

he/him/his
Pulmonology & Sleep Medicine

Biography

Naftali Kaminski, MD, chief of Yale Medicine Pulmonary, Critical Care and Sleep Medicine, is a leader in improving the understanding and treatment of chronic lung diseases. He has a particular interest in idiopathic pulmonary fibrosis, a disease characterized by progressive scarring of the lungs, and in chronic obstructive pulmonary disease and asthma.

Dr. Kaminski leads the Kaminski Lab at Yale School of Medicine, where researchers apply cutting-edge technologies that measure changes in the sequence, expression or regulation of all the genes in the human genome in efforts to learn more about the roles of genome networks and biomarkers in chronic lung disease.

“Pulmonary fibrosis was an understudied and poorly understood disease, with high mortality and morbidity,” says Dr. Kaminiski, who is a professor of medicine (pulmonary) at Yale School of Medicine “I thought that by shifting the focus to human
relevant pathways and mechanisms we can have an impact, and we have.”

Titles

  • Boehringer Ingelheim Pharmaceuticals, Inc. Professor of Medicine (Pulmonary)
  • Section Chief, Pulmonary, Critical Care & Sleep Medicine

Education & Training

  • MD
    Hebrew University (1989)
  • BM
    Hebrew University (1985)

Languages Spoken

  • English
  • עברית (Hebrew)
  • ייִדיש (Yiddish)

Additional Information

Biography

Naftali Kaminski, MD, chief of Yale Medicine Pulmonary, Critical Care and Sleep Medicine, is a leader in improving the understanding and treatment of chronic lung diseases. He has a particular interest in idiopathic pulmonary fibrosis, a disease characterized by progressive scarring of the lungs, and in chronic obstructive pulmonary disease and asthma.

Dr. Kaminski leads the Kaminski Lab at Yale School of Medicine, where researchers apply cutting-edge technologies that measure changes in the sequence, expression or regulation of all the genes in the human genome in efforts to learn more about the roles of genome networks and biomarkers in chronic lung disease.

“Pulmonary fibrosis was an understudied and poorly understood disease, with high mortality and morbidity,” says Dr. Kaminiski, who is a professor of medicine (pulmonary) at Yale School of Medicine “I thought that by shifting the focus to human
relevant pathways and mechanisms we can have an impact, and we have.”

Titles

  • Boehringer Ingelheim Pharmaceuticals, Inc. Professor of Medicine (Pulmonary)
  • Section Chief, Pulmonary, Critical Care & Sleep Medicine

Education & Training

  • MD
    Hebrew University (1989)
  • BM
    Hebrew University (1985)

Languages Spoken

  • English
  • עברית (Hebrew)
  • ייִדיש (Yiddish)

Additional Information